NGL Fine Chem Limited

NSE: NGLFINE · Pharmaceuticals · sector

₹2,624.10NSE close 2026-10-26

Key numbers

Market cap₹1,621 cr

Price₹2,624.10

52w high / low₹3,602 / ₹1,271

P/E28.3xSector median 27.9x

P/B4.9xSector median 2.9x

Book value₹532.9

Dividend yield0.07%Sector median 0.48%

ROE18.7%Sector median 11.7%

ROCE18.3%Sector median 12.3%

OPM15.7%Sector median 14.0%

Debt / equity0.33xSector median 0.16x

EV/EBITDA20.0xSector median 18.6x

Interest cover18.9x

Current ratio1.84x

Sales growth 3y+21.7%Sector median +9.6%

Profit growth 3y+32.9%Sector median +13.3%

PEG0.86x

Last 12 months to Jun 2026, Consolidated. "Sector median" = middle value of 185 companies in Pharmaceuticals (P/E median leaves out loss-making companies). Tap ? for what a number means.

Things to know

Cash ₹44 cr vs borrowings ₹108 cr (FY26): borrowings are higher by ₹64 cr.
Borrowings rose in each of the last 3 years (₹30 cr → ₹108 cr).
Operating profit covered interest 18.9x in the last 12 months.
Operating cash flow was below net profit in 2 of the last 4 years (FY26, FY24).
Revenue was higher than a year earlier in 4 of the last 4 quarters.
Other income was 29% of net profit in the last 12 months.
Dividend paid in 3 of the last 4 financial years.
Price ₹2,624.10 on 2026-10-26: -27.1% from the 52-week high, +106.5% from the 52-week low.

Plain facts from the filings, built by the same fixed rules for every company. A line appears only when the data for it is available. Not a view on the stock.

Charts

Weekly close · high ₹3,428.20 · low ₹1,014.90

Quarterly results

₹ cr	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Revenue	93	89	95	104	120	128	149	139
EBITDA	12	5	6	11	17	22	21	23
OPM %	12.4%	5.7%	6.7%	10.5%	14.3%	17.5%	14.3%	16.7%
Other income	5	-0	-1	6	2	5	2	7
Net profit	10	1	1	9	10	16	13	18
EPS (₹)	15.88	2.07	0.88	14.96	15.58	25.40	21.83	29.78
Revenue YoY					+28.6%	+43.1%	+57.1%	+33.6%
Profit YoY					-1.8%	+1,125.8%	+2,398.1%	+99.1%

Consolidated figures where filed. Latest quarter Jun 2026.

Profit & loss (yearly)

₹ cr	FY23	FY24	FY25	FY26	TTM
Revenue	278	339	368	501	536
EBITDA	34	53	34	73	84
Net profit	20	41	21	48	57
EPS (₹)	33.18	66.88	34.19	77.90	92.59
Revenue growth		+21.8%	+8.7%	+36.0%	+40.5%
Profit growth		+101.6%	-48.9%	+127.9%	+174.0%
Dividend / share (₹)	–	1.75	1.75	1.75

Compounded growth	3 years	5 years	Last 12 months
Sales	+21.7%	–	+40.5%
Net profit	+32.9%	–	+174.0%
EPS	+32.9%	–	–
Share price	–	+11.6% (2y)	+76.0%

Balance sheet

₹ cr	FY23	FY24	FY25	FY26
Shareholders' equity	223	263	282	329
Borrowings	30	32	73	108
Cash & equivalents	52	55	66	44
Total assets	287	356	433	546
Fixed assets	88	85	142	164
Capital work in progress	26	46	50	95
Investments	0	0	0	0
Receivables	66	90	82	131
Inventory	27	43	51	70
Payables	25	49	58	65

Year-end figures from the March annual filing.

Cash flow

₹ cr	FY23	FY24	FY25	FY26
Cash from operations	35	20	36	43
Cash from investing	-27	-27	-35	-71
Cash from financing	-1	-1	-1	30
Capex	31	29	131	90
Free cash flow	4	-8	-95	-47

Free cash flow = cash from operations − capex.

Ratios by year

₹ cr	FY23	FY24	FY25	FY26
ROE %	9.2%	15.7%	7.5%	14.6%
ROCE %	11.3%	18.9%	8.5%	15.5%
Debtor days	86	97	81	95
Inventory days	70	100	103	107
Payable days	64	114	115	98
Cash conversion cycle (days)	92	83	69	104
Working capital days	137	136	115	92

Shareholding

Holder	% (2026-09-30)
Promoters	72.49%
FIIs	0.04%
DIIs	0.00%
of which Mutual funds	0.00%
Public (non-institutions)	27.46%

Quarter	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026	Sep 2026
Promoters %	72.74%	72.74%	72.74%	72.74%	72.74%	72.74%	72.49%	72.49%

Promoter group	%
Rajesh Narayan Lawande	21.89%
Rahul Jayant Nachane	17.54%
Sunita Sandeep Potdar	13.14%
Ajita Rahul Nachane	11.55%
PCI Ferrmone Chemicals India Private Limited	8.38%
Pushpa Narayan Lawande	0.00%

12,939 shareholders. Pledged: – of promoter shares.

Peers in Pharmaceuticals

Company	Market cap	P/E	P/B	ROE	ROCE	OPM	Sales 3y	Div yield
SUNPHARMA	₹4,17,478 cr	34.5x	5.0x	15.5%	18.7%	28.6%	+10.0%	0.94%
DIVISLAB	₹2,39,825 cr	82.1x	14.3x	18.4%	23.0%	34.7%	+10.8%	0.34%
TORNTPHARM	₹1,53,999 cr	72.7x	18.4x	27.3%	15.1%	32.3%	+13.3%	0.84%
ZYDUSLIFE	₹1,15,808 cr	25.9x	4.3x	17.7%	16.8%	27.2%	+16.4%	0.95%
LAURUSLABS	₹1,11,232 cr	101.6x	21.0x	22.4%	20.8%	28.0%	+4.1%	0.08%
CIPLA	₹1,09,464 cr	32.5x	3.2x	10.3%	13.2%	17.7%	+7.4%	1.18%
DRREDDY	₹1,09,460 cr	33.9x	2.9x	9.0%	10.1%	15.5%	+11.0%	0.61%
MANKIND	₹95,486 cr	46.7x	5.9x	13.4%	13.8%	25.1%	+17.7%	0.04%
AUROPHARMA	₹91,489 cr	24.9x	2.4x	10.5%	12.8%	20.0%	+10.6%	0.26%
NGLFINE	₹1,621 cr	28.3x	4.9x	18.7%	18.3%	15.7%	+21.7%	0.07%

All 185 companies in Pharmaceuticals →

Dividends & corporate actions

Ex-date	Action	Detail
2026-08-18	Dividend	Dividend - Rs 1.75 Per Share
2025-08-12	Dividend	Dividend - Rs 1.75 Per Share
2024-08-16	Dividend	Annual General Meeting/Dividend - Rs 1.75 Per Share
2023-08-18	Dividend	Annual General Meeting/Dividend - Rs 1.75 Per Share

Documents

Links go to the original files on the exchange website.

About the company

Pharmaceutical: Manufacturing of pharmaceuticals and intermediates for usage in veterinary and human health


Sector	Healthcare
Industry	Pharmaceuticals
Sub-industry	Pharmaceuticals
Symbol	NGLFINE
BSE code	524774
ISIN	INE887E01022
Face value	₹5.0
Incorporated	1981-12-18
Website	https://www.nglfinechem.com
Plants (India / abroad)	4 / 0

From the company's filings (BRSR FY26).

Data built 2026-10-22 from NSE company filings (XBRL: Integrated Filing - Financials + financial results), NSE shareholding & pledge data; price = NSE close 2026-10-26.